ENOV — Enovis Corporation Stock Price, Chart & AI Report

Neutral Dec 8, 2025 • 17:34 UTC The Motley Fool • Cory Renauer

An Enovis (ENOV) Insider Bets Big on the Stock With a Purchase of 2,468 Shares

John Kleckner, Principal Accounting Officer of Enovis Corporation, purchased 2,468 shares on Nov. 25, 2025, signaling potential confidence in the company despite a challenging year with significant quarterly losses.

ENOV insider trading orthopedic medical devices stock purchase financial performance

Sentiment note

Mixed signals: Stock down 38.6% in a year with significant quarterly losses, but insider purchase suggests potential recovery and growing segment sales (Recon sales up 12%, P&R sales up 6% year-over-year)

Positive Aug 8, 2025 • 13:00 UTC GlobeNewswire Inc. • Kyle Rose

Enovis to Participate in Upcoming Investor Conferences

Enovis Corporation will participate in three investor conferences in August and September 2025, including Canaccord Genuity, Wells Fargo Healthcare, and Baird Global Healthcare Conferences.

ENOV investor conferences medical technology healthcare stock market

Sentiment note

Company is actively engaging with investors, showcasing growth and participation in multiple healthcare conferences, indicating confidence in its market position and future prospects

Positive Aug 7, 2025 • 11:32 UTC The Motley Fool • Jesterai

Enovis (ENOV) Q2 Revenue Rises 7%

Medical technology company Enovis reported Q2 2025 revenue of $564.5 million, up 7% year-over-year, beating analyst estimates. The company raised full-year guidance and saw strong performance in its Reconstructive segment, despite ongoing integration and regulatory challenges.

ENOV medical technology orthopedics earnings report revenue growth acquisitions

Sentiment note

Exceeded revenue and earnings estimates, raised full-year guidance, showed strong growth in Reconstructive segment (11% reported growth), and demonstrated strategic focus on innovation and international expansion

Positive May 26, 2025 • 14:46 UTC GlobeNewswire Inc. • Na

Orthopedic Braces & Supports Market Focused Insights 2025-2030, with Key Vendor Profiles for BREG, Bauerfeind, DeRoyals, Enovis, Ottobock, Ossur and Tynor

The orthopedic braces and supports market is projected to grow at a CAGR of 5.04% from 2024 to 2030, driven by the increasing burden of orthopedic conditions, sports-related injuries, and the development of smart and custom-made braces.

ENOV orthopedic braces supports market growth sports injuries smart braces

Sentiment note

Enovis is highlighted for launching the DonJoy ROAM knee brace, indicating its focus on product innovation and addressing market needs.

Positive Feb 26, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

Enovis Announces Planned CEO Succession Process

Enovis Corporation announced that CEO Matt Trerotola will retire, and the company is actively searching for his successor. Trerotola will remain as an executive advisor for a year to facilitate a smooth transition.

ENOV Enovis Corporation CEO retirement leadership transition

Sentiment note

The article portrays Enovis Corporation in a positive light, highlighting the company's strong position, focus on continuous improvement, and commitment to finding a growth-oriented leader to succeed the retiring CEO. The company's transformation into a leading global MedTech innovator under Trerotola's leadership is also noted.

Positive Jan 17, 2025 • 11:00 UTC GlobeNewswire Inc. • N/A

Enovis™ Announces Leadership Change to International Surgical Business

Enovis, a global medical technology company, announced that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. Visentin is an experienced MedTech executive who previously held leadership roles at BD, Stryker, and Johnson & Johnson Depuy Synthes.

ENOV BDX SYK JNJ Enovis Davide Visentin Benjamin Reinmann MedTech

Sentiment note

The article highlights Enovis' growth and success in the international surgical business, as well as its plans to further expand and innovate under the new leadership of Davide Visentin.

Neutral Sep 5, 2024 • 10:00 UTC GlobeNewswire Inc. • Global Market Insights Inc.

Manual Cutting Equipment Market to record USD 24.6 Bn by 2032, Says Global Market Insights Inc.

The manual cutting equipment market is predicted to reach USD 24.6 billion by 2032, driven by the growing construction industry and demand for efficient cutting tools. The oxy-fuel segment and the construction sector are expected to witness significant growth during this period, particularly in Europe.

AIQUY ENOV ITW KMT manual cutting equipment construction industry oxy-fuel technology Europe

Sentiment note

The article mentions Enovis as a major participant in the manual cutting equipment market, but does not provide any insights into the company's performance or outlook.

Positive Jul 15, 2024 • 13:30 UTC Zacks Investment Research • N/A

Enovis' (ENOV) New System to Aid Reverse Shoulder Prosthesis - Zacks Investment Research

Enovis has introduced the AltiVate Reverse Glenoid System, a new solution for reverse shoulder arthroplasty. The system offers modular and augmented baseplates, providing surgeons with more options to improve implant longevity and optimize patient outcomes.

ENOV Enovis AltiVate Reverse Glenoid System Reverse Shoulder Arthroplasty

Sentiment note

The article highlights the introduction of Enovis' new AltiVate Reverse Glenoid System, which is expected to expand the company's product offerings and provide more options for surgeons in reverse shoulder arthroplasty procedures.

Positive Jul 12, 2024 • 13:02 UTC Zacks Investment Research • N/A

What Awaits Quest Diagnostics (DGX) in Q2 Earnings Release? - Zacks Investment Research

Quest Diagnostics is set to report its second-quarter 2024 earnings on July 23. The company's legacy base business and advanced diagnostics offerings are expected to drive growth, while the decline in COVID-19 testing revenues may be a challenge.

DGX HIMS HCA ENOV Quest Diagnostics earnings diagnostics COVID-19

Sentiment note

The article mentions Enovis as a stock worth considering, as it has a positive Earnings ESP and a Zacks Rank #2, indicating a higher chance of beating earnings estimates.

Unknown Jun 24, 2024 • 12:16 UTC Zacks Investment Research • Nalak Das

5 Medical Info Systems Stock to Buy for a Stable Portfolio

We have narrowed our search to five medical info systems stocks. These are: HIMS, ENOV, LUNG, PHR, LAB.

PHR LUNG HIMS ENOV

Unknown Jun 13, 2024 • 17:45 UTC Zacks Investment Research • Zacks Equity Research

Compelling Reasons to Hold on to HCA Healthcare (HCA) Stock

HCA Healthcare (HCA) remains well-poised for growth on the back of improved revenues, a well-diversified healthcare portfolio and solid cash-generating abilities.

HCA LGND OGN ENOV

Unknown Jun 5, 2024 • 15:54 UTC Zacks Investment Research • Zacks Equity Research

Ensign Group (ENSG) Buys Facilities in Arizona & Colorado

Ensign Group (ENSG) expands its footprint by acquiring skilled nursing facilities in Arizona and Colorado, enhancing its healthcare services and real estate portfolio.

LGND ENSG OGN ENOV